Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
Go back to Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM| (NASDAQ: ORGO) | Delayed: 1.86 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.86 | 52 Week High | $ | |||
| Open | $1.86 | 52 Week Low | $ | |||
| Day High | $1.86 | P/E | N/A | |||
| Day Low | $1.86 | EPS | $ | |||
| Volume | 4,491 | |||||
